FDA grants approval of a Phase 3 pivotal study for ST10 for the treatment of iron deficiency anaemia in chronic kidney disease

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia (IDA) in pre-dialysis patients with chronic kidney disease (CKD).
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Urology / Nephrology Source Type: news